Skip to main content

Table 4 Comparison of Annualized CFFPR Data between MWCFC and other US Patients

From: Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis

Patient Characteristics MWCFC, n = 114 CFFPR 2014
n = 14,394
p
Enrollment Annualized for 2014
Male sex, fraction 0.46 0.46 0.48 0.79
Age, Years, mean (SD) 28 (12) 27 (12) 27 (12) 0.71
FEV1, Percent Predicted, mean (SD) 70 (22) 80 (23) 77 (27) 0.094
Height, cm, mean (SD) 167 (9.95) 167 (10.2) 166 (10) 0.39
Weight-for-age z-score, mean (SD) −0.17 (0.98) −0.20 (0.93) −0.29 (1.1) 0.34
Pulmonary exacerbations in year prior to enrollment, median (range) 1 (0–7) 1 (0–6) 1 (0–14) 0.55
Pulmonary exacerbations in year prior to enrollment, mean (SD) 1.7 (1.7) 1 (1.2) 1.1 (1.5) > 0.99
Patients with no pulmonary exacerbations, n (fraction affected) 79 (0.69) 63 (0.56) 7054 (0.52) 0.46
Diabetes, n (fraction affected) 25 (0.22) 26 (0.23) 4423 (0.31) 0.073
Pancreatic Sufficiency, n (fraction affected) 9 (0.079) 19 (0.17) 2239 (0.16) 0.84
CF related arthropathy, n (fraction affected) 8 (0.07) 10 (0.088) 697 (0.048) 0.085
5-Year Predicted Survival, median (range) 0.959 (0.094 to > 0.999) 0.973 (0.464–0.999) 0.967 (0.0949–0.999) 0.17
Home Altitude, m, mean (SD) 1305 (442)
Infections Present, n (fraction affected)
 Methicillin Sensitive S aureus 51 (0.45) 67 (0.59) 7937 (0.55) 0.5
 Methicillin Resistant S aureus 21 (0.18) 33 (0.29) 5001 (0.35) 0.23
P aeruginosa 70 (0.61) 84 (0.74) 10,096 (0.70) 0.47
B cepacia complex 3 (0.026) 5 (0.044) 782 (0.054) 0.78
S maltophilia 7 (0.061) 26 (0.23) 2970 (0.21) 0.65
Achromobacter spp 5 (0.044) 11 (0.096) 1579 (0.11) 0.76
Candida spp 17 (0.15) 17 (0.15) 3100 (0.22) 0.11
Aspergillus 12 (0.11) 26 (0.23) 3091 (0.21) 0.82
Mycobacterium avium-intracellulare complexa 1 (0.0088) 8 (0.082) 730 (0.069) 0.74
Mycobacterium abscessusa 3 (0.027) 5 (0.052) 527 (0.05) > 0.99
Treatments in use, n (fraction affected)
 Any Form of Inhaled Tobramycin 38 (0.33) 71 (0.62) 8069 (0.58) 0.38
 Inhaled Aztreonam 40 (0.35) 47 (0.41) 4977 (0.36) 0.25
 Oral Azithromycin 62 (0.54) 67 (0.59) 8595 (0.60) 0.91
 Inhaled Hypertonic Saline 71 (0.62) 82 (0.72) 9611 (0.69) 0.54
 Inhaled DNase 101 (0.89) 106 (0.93) 12,168 (0.87) 0.087
  1. aFractions reported reflect that 97 MWCFC and 10,618 CFFPR patients had acid fast bacterial cultures performed in 2014. MWCFC patients were more likely to undergo acid fast cultures than non-study patients (p = 0.008, χ-square test)
\